A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal …
L Paz-Ares, JM Sanchez, A Garcia-Velasco… - Journal of Clinical …, 2006 - ascopubs.org
7020 Background: The EGFR TK inhibitor erlotinib is a standard treatment in previously
treated NSCLC p. Recently, EGFR gene mutations have been reported to be a predictor of …
treated NSCLC p. Recently, EGFR gene mutations have been reported to be a predictor of …
Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with …
N Yamamoto, A Horiike, Y Fujisaka… - Cancer chemotherapy …, 2008 - Springer
Purpose The objectives of this phase I dose-finding study of erlotinib were to investigate the
toxicity profile, to confirm the acceptable toxicity of doses up to 150 mg/day, and to assess …
toxicity profile, to confirm the acceptable toxicity of doses up to 150 mg/day, and to assess …
[HTML][HTML] Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer
T Mok, Y Wu, JS Au, C Zhou, L Zhang, RP Perng… - Journal of Thoracic …, 2010 - Elsevier
Introduction: Erlotinib is an epidermal growth factor receptor tyrosine kinase inhibitor that
significantly increases survival for patients with previously treated advanced non-small cell …
significantly increases survival for patients with previously treated advanced non-small cell …
[HTML][HTML] Erlotinib (tarceva) for the treatment of non–small-cell lung cancer and pancreatic cancer
CM Rocha-Lima, LE Raez - Pharmacy and Therapeutics, 2009 - ncbi.nlm.nih.gov
Erlotinib (Tarceva) is a small-molecule, orally dosed, anti-cancer drug that inhibits the
epidermal growth factor receptor. Randomized, controlled clinical studies have …
epidermal growth factor receptor. Randomized, controlled clinical studies have …
[HTML][HTML] Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer
NW Choong, AM Mauer, DJ Haraf, E Lester… - Journal of Thoracic …, 2008 - Elsevier
Introduction This Phase I trial aimed to determine the maximum-tolerated-dose of erlotinib
administered with two standard chemoradiotherapy regimens for non-small cell lung cancer …
administered with two standard chemoradiotherapy regimens for non-small cell lung cancer …
Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non–small cell lung cancer
Abstract Background The NCIC Clinical Trials Group conducted the BR. 21 trial, a
randomized placebo-controlled trial of erlotinib (an epidermal growth factor receptor tyrosine …
randomized placebo-controlled trial of erlotinib (an epidermal growth factor receptor tyrosine …
Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC)
MH Cohen, JR Johnson, S Chattopadhyay… - The …, 2010 - academic.oup.com
Abstract Learning Objectives After completing this course, the reader will be able to:
Evaluate the relationship between EGFR mutation status and clinical outcomes reported in …
Evaluate the relationship between EGFR mutation status and clinical outcomes reported in …
Long survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HCl (OSI-774) and chemotherapy: sub-group analysis of …
VA Miller, R Herbst, D Prager… - Journal of Clinical …, 2004 - ascopubs.org
7061 Background: Erlotinib (Tarceva) is a potent HER1/EGFR tyrosine kinase inhibitor (TKI).
Monotherapy trials of EGFR-TKIs have suggested never smokers and pts with …
Monotherapy trials of EGFR-TKIs have suggested never smokers and pts with …